Karyopharm Therapeutics Inc (KPTI) was Initiated by Raymond James to “Outperform” and the brokerage firm has set the Price Target at $13. Raymond James advised their investors in a research report released on May 27, 2016.
Many Wall Street Analysts have commented on Karyopharm Therapeutics Inc. Shares were Reiterated by Wedbush on Mar 16, 2016 to “Outperform” and Lowered the Price Target to $ 16 from a previous price target of $38 .
Karyopharm Therapeutics Inc opened for trading at $9.51 and hit $10.12 on the upside on Wednesday, eventually ending the session at $9.69, with a gain of 2.76% or 0.26 points. The heightened volatility saw the trading volume jump to 2,90,716 shares. Company has a market cap of $348 M.
In a different news, on Dec 10, 2015, Mansoor Raza Mirza (director) sold 15,000 shares at $15.01 per share price. According to the SEC, on Apr 8, 2015, Ran Frenkel (EVP, WW Development Operations) purchased 3,000 shares at $31.22 per share price. On Apr 6, 2015, Justin A Renz (CFO) purchased 5,000 shares at $29.71 per share price, according to the Form-4 filing with the securities and exchange commission.
Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of drugs directed against nuclear transport targets for the treatment of cancer and other diseases. The Company is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibits the nuclear export protein XPO1. The Company is seeking the regulatory approval and commercialization of its lead drug candidate selinexor (KPT-330) as a single orally administered agent in cancer indications with unmet clinical need initially for hematologic malignancies. It is also advancing the clinical development of selinexor in multiple solid tumor indications. The Company has initiated three registration-directed trials in hematological cancers with selinexor and anticipates initiating a fourth registration-directed trial.